EQS-Ad-hoc: MEDIQON Group AG / Key word(s): Capital Increase
The private placement of the capital increase resolved on December 12, 2022, excluding subscription rights by issuing new shares was successfully completed in the amount of 1,067,267 new shares. The increase is equivalent to c. 7.1% of the company’s existing share capital. The subscription price was EUR 14.50 per new share, resulting in gross proceeds of c. EUR 15.5m.
Subject to the registration in the Commercial Register, the share capital increases from EUR 14,999,333.00 to EUR 16,066,600.00.
13-Dec-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | MEDIQON Group AG |
Herzog-Adolph-Strasse 2 | |
61462 Königstein im Taunus | |
Germany | |
Phone: | +49 (0) 6174-9687040 |
Fax: | +49 (0) 6174-9687043 |
E-mail: | ir@mediqon-group.de |
Internet: | www.mediqon-group.de |
ISIN: | DE0006618309, DE000A254TL0 |
WKN: | 661830, A254TL |
Listed: | Regulated Unofficial Market in Berlin, Frankfurt (Basic Board), Stuttgart |
EQS News ID: | 1511161 |
End of Announcement | EQS News Service |
|
1511161 13-Dec-2022 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.